News

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose hypertension is either uncontrolled by or resistant to existing medicines.
NEW YORK – QuidelOrtho announced Monday an integration deal making fecal biomarker testing from Bühlmann Laboratories available on QuidelOrtho's Vitros system. The Bühlmann fecal tests detect ...
A rare metabolic condition affecting children may have to wait longer for a potential one-time treatment as Ultragenyx ...
Titer tests are what's used "to help you determine if you currently have immunity to certain diseases due to past infection or vaccination,” says Dr. Alison Mitzner, a New York board-certified ...
Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...
Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...
Quest Diagnostics to offer US FDA-approved Fujirebio blood test for Alzheimer's disease: Secaucus, New Jersey Friday, July 11, 2025, 14:00 Hrs [IST] Quest Diagnostics, a leader in ...
Berkeley scientists have developed a smartphone-based biosensor that mimics coffee-ring physics to detect disease proteins ...
Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510 (k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic ...
Ixico said it was contracted by Fujirebio Diagnostics Inc, a Tokyo-based biomarker research company, to assist with the development of a new blood-based test for Alzheimer's disease called Lumipulse.